WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Amgen

AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

www.amgen.com

Amgen RSS Channel

Filters
List of articles in category Amgen
Title Published Date
Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies 17 September 2020
Amgen and Adaptive Biotechnologies announce strategic partnership to develop a therapeutic to prevent or treat COVID-19 02 April 2020
Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts 26 March 2020
Amgen, Cytokinetics and Servier announce continuation of GALACTIC-HF following planned interim analysis 26 February 2020
Free "LabXchange" science education accelerator launched by Amgen Foundation and Harvard's Faculty of Arts and Sciences 22 January 2020
Amgen announces global diagnostic collaborations 13 January 2020
Amgen commences strategic collaboration with BeiGene to expand oncology presence in China 06 January 2020
Amgen and Allergan submit Biologics License Application for ABP 798, biosimilar candidate to Rituxan® (rituximab) 19 December 2019
Amgen completes acquisition of Otezla® (apremilast) 21 November 2019
Amgen and the Duke Clinical Research Institute announce initiation of first large-scale registry to evaluate real-world lipid management and the effectiveness of PCSK9 inhibitors 18 November 2019
Amgen recommends rejection of 'mini-tender' offer from TRC Capital Corporation 23 October 2019
Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia 21 October 2019
Amgen announces positive results from two Phase 3 BLINCYTO® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia 25 September 2019
Amgen to acquire Otezla® for $13.4 billion in cash 26 August 2019
Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan® (rituximab) 22 August 2019
Amgen and Allergan's MVASI™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States 23 July 2019
FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab) 17 June 2019
Amgen joins with community oncology networks for new research collaboration 28 May 2019
Amgen and Syapse enter precision medicine collaboration in oncology 06 May 2019
Amgen ignites a social fitness movement to support the fight against heart disease and cancer 02 May 2019
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Amgen
  4. Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.